
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Therapy may have unexpected benefits...
Jonny Hawkins is a cartoonist, whose latest book,




